Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.
2.

In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir.

Colledge D, Civitico G, Locarnini S, Shaw T.

Antimicrob Agents Chemother. 2000 Mar;44(3):551-60.

3.

In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus.

Shaw T, Amor P, Civitico G, Boyd M, Locarnini S.

Antimicrob Agents Chemother. 1994 Apr;38(4):719-23.

4.

Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model.

Le Guerhier F, Pichoud C, Guerret S, Chevallier M, Jamard C, Hantz O, Li XY, Chen SH, King I, Trépo C, Cheng YC, Zoulim F.

Antimicrob Agents Chemother. 2000 Jan;44(1):111-22.

5.

Animal models for the study of HBV infection and the evaluation of new anti-HBV strategies.

Zoulim F, Berthillon P, Guerhier FL, Seigneres B, Germon S, Pichoud C, Cheng YC, Trepo C.

J Gastroenterol Hepatol. 2002 Dec;17 Suppl:S460-3.

PMID:
12534778
6.

Effect of nucleoside analogue therapy on duck hepatitis B viral replication in hepatocytes and bile duct epithelial cells in vivo.

Nicoll A, Locarnini S, Chou ST, Smallwood R, Angus P.

J Gastroenterol Hepatol. 2000 Mar;15(3):304-10.

PMID:
10764033
8.

Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine.

Severini A, Liu XY, Wilson JS, Tyrrell DL.

Antimicrob Agents Chemother. 1995 Jul;39(7):1430-5.

9.

Combination therapy for chronic hepatitis B.

Fontana RJ, Lok AS.

Hepatology. 1997 Jul;26(1):234-7. No abstract available.

PMID:
9214476
10.

The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo.

Lin E, Luscombe C, Wang YY, Shaw T, Locarnini S.

Antimicrob Agents Chemother. 1996 Feb;40(2):413-18.

11.

Inhibition of human and duck hepatitis B virus by 2',3'-dideoxy-3'-fluoroguanosine in vitro.

Schröder I, Holmgren B, Oberg M, Löfgren B.

Antiviral Res. 1998 Jan;37(1):57-66.

PMID:
9497073
12.

Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model.

Seignères B, Martin P, Werle B, Schorr O, Jamard C, Rimsky L, Trépo C, Zoulim F.

Antimicrob Agents Chemother. 2003 Jun;47(6):1842-52.

13.

The SATE pronucleotide approach applied to acyclovir: part II. Effects of bis(SATE)phosphotriester derivatives of acyclovir on duck hepatitis B virus replication in vitro and in vivo.

Hantz O, Périgaud C, Borel C, Jamard C, Zoulim F, Trépo C, Imbach JL, Gosselin G.

Antiviral Res. 1999 Jan;40(3):179-87.

PMID:
10027652
14.

Antiviral effects of PNA in duck hepatitis B virus infection model.

Chen ZY, Cheng AC, Wang MS, Xu DW, Zeng W, Li Z.

Acta Pharmacol Sin. 2007 Oct;28(10):1652-8.

15.

Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses.

Seignères B, Pichoud C, Martin P, Furman P, Trépo C, Zoulim F.

Hepatology. 2002 Sep;36(3):710-22.

PMID:
12198665
16.

Inhibition of duck hepatitis B virus replication by 2',3'-dideoxy-3'-fluoroguanosine in vitro and in vivo.

Hafkemeyer P, Keppler-Hafkemeyer A, al Haya MA, von Janta-Lipinski M, Matthes E, Lehmann C, Offensperger WB, Offensperger S, Gerok W, Blum HE.

Antimicrob Agents Chemother. 1996 Mar;40(3):792-4.

17.
18.

Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication.

Marion PL, Salazar FH, Winters MA, Colonno RJ.

Antimicrob Agents Chemother. 2002 Jan;46(1):82-8.

19.
20.

DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection.

Thermet A, Buronfosse T, Werle-Lapostolle B, Chevallier M, Pradat P, Trepo C, Zoulim F, Cova L.

J Gen Virol. 2008 May;89(Pt 5):1192-201. doi: 10.1099/vir.0.83583-0.

PMID:
18420797

Supplemental Content

Support Center